

statement, may request it at the time of the public comment period on December 9, 2020 at 11:55 a.m., EST.

Written Public Comment: The public is welcome to submit written comments in advance of the meeting. Comments should be submitted in writing according to the instructions provided. The deadline for receipt of written public comment is December 6, 2020, EST. All requests must contain the name, address, and organizational affiliation of the speaker, as well as the topic being addressed. Written comments received in advance of the meeting will be included in the official record of the meeting.

Matters to be Considered: The agenda will include discussions and updates on: (1) TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens; (2) Latent Tuberculosis Infection (LTBI) Community Engagement; (3) Bedaquiline + Pretomanid + Linezolid (BPaL) Clinical Guidance; (4) Nitrosamine Impurities in Rifamycins; and (5) Electronic Directly Observed Therapy (eDOT). Agenda items are subject to change as priorities dictate.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,

Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2020-24505 Filed 11-4-20; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Board of Scientific Counselors, Center for Preparedness and Response (BSC, CPR); Correction

Notice is hereby given of a change in the meeting of the Board of Scientific Counselors, Center for Preparedness and Response (BSC, CPR); October 26, 2020, 12:30 p.m. to 3:30 p.m., EDT; which was published in the **Federal Register** on September 14, 2020 Volume 85, Number 178, page 56618.

The meeting time, matters to be considered and contact information should read as follows:

DATES: The webinar meeting will be held on October 26, 2020, from 12:30 p.m. to 1:30 p.m., EDT.

SUPPLEMENTARY INFORMATION:

Purpose: This Board is charged with providing advice and guidance to the Secretary, Department of Health and Human Services (HHS), the Assistant Secretary for Health (ASH), the Director, Centers for Disease Control and Prevention (CDC), and the Director, Center for Preparedness and Response (CPR), concerning strategies and goals for the programs and research within CPR, monitoring the overall strategic direction and focus of the CPR Divisions and Offices, and administration and oversight of peer review for CPR scientific programs. For additional information about the Board, please visit: <https://www.cdc.gov/cpr/bsc/index.htm>.

Matters to be Considered: The agenda will include: (1) CPR Updates from the Director; and (2) BSC, CPR Polio Containment Workgroup (PCWG) Update.

FOR FURTHER INFORMATION CONTACT:

Dometa Ouisley, Office of Science and Public Health Practice, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H21-6, Atlanta, Georgia 30329, Telephone: (404) 639-7450; Email: OPHPR.BSC.Questions@cdc.gov.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,

Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2020-24506 Filed 11-4-20; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Lead Exposure and Prevention Advisory Committee (LEPAC); Correction

Notice is hereby given of a change in the date for the solicitation of nominations for appointment to the Lead Exposure and Prevention Advisory Committee (LEPAC); December 15, 2021 which was published in the **Federal Register** on October 28, 2020 Volume 85, Number 209, pages 68328-68329.

The notice should read as follows:

DATES: Nominations for membership on the LEPAC must be received no later than November 27, 2020. Packages received after this time will not be considered for the current membership cycle.

ADDRESSES: All nominations should be emailed to LEPAC@cdc.gov.

FOR FURTHER INFORMATION CONTACT: Ms. Perri Ruckart, M.P.H., Designated Federal Officer, National Center for Environmental Health, CDC, 4770 Buford Highway, Atlanta, GA 30341, 770-488-3300, PRuckart@cdc.gov.

SUPPLEMENTARY INFORMATION: The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,

Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2020-24507 Filed 11-4-20; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Statement of Organization, Functions, and Delegations of Authority

Part C (Centers for Disease Control and Prevention) of the Statement of Organization, Functions, and Delegations of Authority of the Department of Health and Human Services (45 FR 67772-76, dated October 14, 1980, and corrected at 45 FR